Delamanid for multidrug-resistant pulmonary tuberculosis.

By M. T. Gler, Vija Skripconoka, Epifanio Sanchez-Garavito, He-ping Xiao, Jose L Cabrera-Rivero, D. Vargas-Vasquez, M. Gao, Mohamed Awad, Seung-kyu Park, T. Shim and 11 more. New England Journal of Medicine, 2012

690 citations recorded by the source corpus.

Subfields: Epidemiology, Infectious Diseases, Organic Chemistry

View Paper: https://www.semanticscholar.org/paper/4195c4c91fd066a3c8396d143c7645dd799c8549

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. N. Bulabula
2. Fatima Razia
3. M. Khan
4. P. Katoto
5. S. Hasnain
6. Timothy D McHugh
7. J. Chakaya
8. S. Mfinanga

Citations in the corpus

• Global Tuberculosis Report 2020 – Reflections on the Global TB burden, treatment and prevention efforts (2021, background): “Such regimens should be urgently scaled-up to improve outcomes, minimize side effects and improve adherence along with point-of-care molecular drug susceptibility testing of second line MDR-TB drugs (Bisimwa et al., 2020; Cox et al., 2018; Diacon et al., 2014; Gler et al., 2012).”